1. Home
  2. MTCH vs CYTK Comparison

MTCH vs CYTK Comparison

Compare MTCH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Match Group Inc.

MTCH

Match Group Inc.

HOLD

Current Price

$31.20

Market Cap

7.6B

Sector

Technology

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$62.60

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTCH
CYTK
Founded
1986
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
8.0B
IPO Year
2015
2004

Fundamental Metrics

Financial Performance
Metric
MTCH
CYTK
Price
$31.20
$62.60
Analyst Decision
Hold
Strong Buy
Analyst Count
11
16
Target Price
$35.55
$82.38
AVG Volume (30 Days)
3.4M
2.3M
Earning Date
02-03-2026
02-26-2026
Dividend Yield
2.40%
N/A
EPS Growth
N/A
N/A
EPS
2.15
N/A
Revenue
$3,469,367,000.00
$87,211,000.00
Revenue This Year
$2.06
$339.72
Revenue Next Year
$3.38
$79.08
P/E Ratio
$14.72
N/A
Revenue Growth
N/A
2609.26
52 Week Low
$26.39
$29.31
52 Week High
$39.20
$70.98

Technical Indicators

Market Signals
Indicator
MTCH
CYTK
Relative Strength Index (RSI) 36.27 47.75
Support Level $31.35 $60.30
Resistance Level $32.15 $65.08
Average True Range (ATR) 0.67 2.91
MACD -0.10 -0.01
Stochastic Oscillator 2.45 45.74

Price Performance

Historical Comparison
MTCH
CYTK

About MTCH Match Group Inc.

Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. The company generates the majority of its revenue from the Tinder segment.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: